{"product_id":"dalstep","title":"Dalstep","description":"\u003ch3 data-start=\"312\" data-end=\"340\"\u003eWhat is Dalfampridine?\u003c\/h3\u003e\r\n\u003cp data-start=\"341\" data-end=\"755\"\u003e\u003cstrong data-start=\"341\" data-end=\"358\"\u003eDalfampridine\u003c\/strong\u003e is an oral medication used as a symptomatic treatment in patients with multiple sclerosis (MS) to improve walking. It is a selective voltage‑gated potassium channel blocker that works by enhancing conduction in demyelinated nerve fibers. By prolonging action potentials in these impaired axons, dalfampridine improves walking speed and endurance in individuals with MS-related walking disability.\u003c\/p\u003e\r\n\u003cp data-start=\"757\" data-end=\"859\"\u003e\u003cem data-start=\"757\" data-end=\"859\"\u003eReference: U.S. FDA Ampyra Prescribing Information (FDA.gov); ClinicalTrials.gov (e.g., NCT00731639)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"861\" data-end=\"864\"\u003e\r\n\u003ch3 data-start=\"866\" data-end=\"923\"\u003eWhat are the other popular names for Dalfampridine?\u003c\/h3\u003e\r\n\u003cp data-start=\"924\" data-end=\"1012\"\u003eDalfampridine is marketed under several brand names, the most widely recognized being:\u003c\/p\u003e\r\n\u003cul data-start=\"1013\" data-end=\"1094\"\u003e\r\n\u003cli data-start=\"1013\" data-end=\"1049\"\u003e\n\u003cstrong data-start=\"1015\" data-end=\"1026\"\u003eAmpyra®\u003c\/strong\u003e in the United States\u003c\/li\u003e\r\n\u003cli data-start=\"1050\" data-end=\"1094\"\u003e\n\u003cstrong data-start=\"1052\" data-end=\"1064\"\u003eFampyra®\u003c\/strong\u003e in many international markets\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1096\" data-end=\"1148\"\u003e\u003cem data-start=\"1096\" data-end=\"1148\"\u003eReference: U.S. FDA; MedlinePlus (MedlinePlus.gov)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1150\" data-end=\"1153\"\u003e\r\n\u003ch3 data-start=\"1155\" data-end=\"1210\"\u003eWhat is the drug classification of Dalfampridine?\u003c\/h3\u003e\r\n\u003cp data-start=\"1211\" data-end=\"1386\"\u003eDalfampridine is classified as a \u003cstrong data-start=\"1244\" data-end=\"1273\"\u003epotassium channel blocker\u003c\/strong\u003e. It belongs to the broader category of \u003cstrong data-start=\"1313\" data-end=\"1385\"\u003eantispastic agents and symptomatic treatments for multiple sclerosis\u003c\/strong\u003e.\u003c\/p\u003e\r\n\u003cp data-start=\"1388\" data-end=\"1470\"\u003e\u003cem data-start=\"1388\" data-end=\"1470\"\u003eReference: U.S. FDA; World Health Organization (WHO) guidelines on MS management\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1472\" data-end=\"1475\"\u003e\r\n\u003ch3 data-start=\"1477\" data-end=\"1527\"\u003eWhat is the mode of action of Dalfampridine?\u003c\/h3\u003e\r\n\u003cp data-start=\"1528\" data-end=\"1892\"\u003eDalfampridine works by blocking voltage‑dependent potassium channels on demyelinated nerve fibers. This blockade prolongs the duration of action potentials, thereby improving the conduction of nerve impulses. As a result, neural transmission is enhanced, which helps improve walking ability in patients with MS who experience conduction block due to demyelination.\u003c\/p\u003e\r\n\u003cp data-start=\"1894\" data-end=\"1992\"\u003e\u003cem data-start=\"1894\" data-end=\"1992\"\u003eReference: PubMed (e.g., Goodman \u0026amp; Gilman’s The Pharmacological Basis of Therapeutics); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1994\" data-end=\"1997\"\u003e\r\n\u003ch3 data-start=\"1999\" data-end=\"2031\"\u003eHow is Dalfampridine used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2032\" data-end=\"2352\"\u003eDalfampridine is used as a \u003cstrong data-start=\"2059\" data-end=\"2084\"\u003esymptomatic treatment\u003c\/strong\u003e for improving walking in adults with multiple sclerosis who have a documented walking disability. It is not a disease‑modifying therapy for MS but rather a treatment aimed at enhancing mobility and quality of life by improving nerve conduction in demyelinated fibers.\u003c\/p\u003e\r\n\u003cp data-start=\"2354\" data-end=\"2433\"\u003e\u003cem data-start=\"2354\" data-end=\"2433\"\u003eReference: American Academy of Neurology (AAN) guidelines; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2435\" data-end=\"2438\"\u003e\r\n\u003ch3 data-start=\"2440\" data-end=\"2514\"\u003eWhat is the recommended dosage and administration for Dalfampridine?\u003c\/h3\u003e\r\n\u003cul data-start=\"2515\" data-end=\"2942\"\u003e\r\n\u003cli data-start=\"2515\" data-end=\"2632\"\u003e\n\u003cstrong data-start=\"2517\" data-end=\"2528\"\u003eDosage:\u003c\/strong\u003e The standard recommended dosage is \u003cstrong data-start=\"2564\" data-end=\"2598\"\u003e10 mg taken orally twice daily\u003c\/strong\u003e (approximately every 12 hours).\u003c\/li\u003e\r\n\u003cli data-start=\"2633\" data-end=\"2942\"\u003e\n\u003cstrong data-start=\"2635\" data-end=\"2654\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2659\" data-end=\"2942\"\u003e\r\n\u003cli data-start=\"2659\" data-end=\"2722\"\u003eDalfampridine tablets should be swallowed whole with water.\u003c\/li\u003e\r\n\u003cli data-start=\"2725\" data-end=\"2833\"\u003eIt can be taken with or without food; however, consistent timing each day is advised for optimal effect.\u003c\/li\u003e\r\n\u003cli data-start=\"2836\" data-end=\"2942\"\u003eDose adjustments are not typically recommended, but caution is needed in patients with renal impairment.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2944\" data-end=\"3036\"\u003e\u003cem data-start=\"2944\" data-end=\"3036\"\u003eReference: U.S. FDA Ampyra Prescribing Information; ClinicalTrials.gov (e.g., NCT00731639)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3038\" data-end=\"3041\"\u003e\r\n\u003ch3 data-start=\"3043\" data-end=\"3109\"\u003eWhat prescribing information is important for Dalfampridine?\u003c\/h3\u003e\r\n\u003cul data-start=\"3110\" data-end=\"3723\"\u003e\r\n\u003cli data-start=\"3110\" data-end=\"3286\"\u003e\n\u003cstrong data-start=\"3112\" data-end=\"3128\"\u003eIndications:\u003c\/strong\u003e Dalfampridine is indicated to improve walking in patients with multiple sclerosis as measured by standardized walking tests (e.g., the Timed 25-Foot Walk).\u003c\/li\u003e\r\n\u003cli data-start=\"3287\" data-end=\"3556\"\u003e\n\u003cstrong data-start=\"3289\" data-end=\"3311\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3316\" data-end=\"3556\"\u003e\r\n\u003cli data-start=\"3316\" data-end=\"3419\"\u003eIt is contraindicated in patients with a history of seizure disorder or those at risk for seizures.\u003c\/li\u003e\r\n\u003cli data-start=\"3422\" data-end=\"3556\"\u003eIt should not be used in patients with moderate to severe renal impairment (typically defined as creatinine clearance \u0026lt;50 mL\/min).\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3557\" data-end=\"3723\"\u003e\n\u003cstrong data-start=\"3559\" data-end=\"3574\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3579\" data-end=\"3723\"\u003e\r\n\u003cli data-start=\"3579\" data-end=\"3655\"\u003ePatients should be evaluated for seizure risk before starting treatment.\u003c\/li\u003e\r\n\u003cli data-start=\"3658\" data-end=\"3723\"\u003eRenal function should be monitored periodically during therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3725\" data-end=\"3814\"\u003e\u003cem data-start=\"3725\" data-end=\"3814\"\u003eReference: U.S. FDA Ampyra Prescribing Information; National Institutes of Health (NIH)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3816\" data-end=\"3819\"\u003e\r\n\u003ch3 data-start=\"3821\" data-end=\"3909\"\u003eWhat safety information, warnings, and cautions are associated with Dalfampridine?\u003c\/h3\u003e\r\n\u003cul data-start=\"3910\" data-end=\"4671\"\u003e\r\n\u003cli data-start=\"3910\" data-end=\"4039\"\u003e\n\u003cstrong data-start=\"3912\" data-end=\"3936\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3941\" data-end=\"4039\"\u003e\r\n\u003cli data-start=\"3941\" data-end=\"4039\"\u003eDizziness, headache, nausea, and insomnia are among the most frequently reported side effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4040\" data-end=\"4518\"\u003e\n\u003cstrong data-start=\"4042\" data-end=\"4066\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4071\" data-end=\"4518\"\u003e\r\n\u003cli data-start=\"4071\" data-end=\"4250\"\u003e\n\u003cstrong data-start=\"4073\" data-end=\"4090\"\u003eSeizure Risk:\u003c\/strong\u003e Dalfampridine may lower the seizure threshold; patients with a history of seizures or conditions predisposing to seizures should use it with extreme caution.\u003c\/li\u003e\r\n\u003cli data-start=\"4253\" data-end=\"4401\"\u003e\n\u003cstrong data-start=\"4255\" data-end=\"4276\"\u003eRenal Impairment:\u003c\/strong\u003e Since dalfampridine is renally excreted, its use in patients with moderate to severe renal dysfunction is contraindicated.\u003c\/li\u003e\r\n\u003cli data-start=\"4404\" data-end=\"4518\"\u003e\n\u003cstrong data-start=\"4406\" data-end=\"4428\"\u003eDrug Interactions:\u003c\/strong\u003e Caution is advised when used with other medications that can lower the seizure threshold.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4519\" data-end=\"4671\"\u003e\n\u003cstrong data-start=\"4521\" data-end=\"4551\"\u003eAdditional Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"4556\" data-end=\"4671\"\u003e\r\n\u003cli data-start=\"4556\" data-end=\"4671\"\u003eIt is important for patients to adhere strictly to the recommended dosage to minimize the risk of adverse events.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4673\" data-end=\"4773\"\u003e\u003cem data-start=\"4673\" data-end=\"4773\"\u003eReference: U.S. FDA Ampyra Prescribing Information; WHO; PubMed literature on dalfampridine safety\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4775\" data-end=\"4778\"\u003e\r\n\u003ch3 data-start=\"4780\" data-end=\"4849\"\u003eWhat drug interactions should be considered with Dalfampridine?\u003c\/h3\u003e\r\n\u003cul data-start=\"4850\" data-end=\"5198\"\u003e\r\n\u003cli data-start=\"4850\" data-end=\"5043\"\u003e\n\u003cstrong data-start=\"4852\" data-end=\"4879\"\u003eCNS-active Medications:\u003c\/strong\u003e\r\n\u003cul data-start=\"4884\" data-end=\"5043\"\u003e\r\n\u003cli data-start=\"4884\" data-end=\"5043\"\u003eConcomitant use with other drugs that lower the seizure threshold (e.g., certain antidepressants, antipsychotics, or stimulants) may increase seizure risk.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5044\" data-end=\"5198\"\u003e\n\u003cstrong data-start=\"5046\" data-end=\"5066\"\u003eRenal Excretion:\u003c\/strong\u003e\r\n\u003cul data-start=\"5071\" data-end=\"5198\"\u003e\r\n\u003cli data-start=\"5071\" data-end=\"5195\"\u003eDrugs that further impair renal function may increase the risk of toxicity, so concurrent use should be managed carefully.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5199\" data-end=\"5271\"\u003e\u003cem data-start=\"5199\" data-end=\"5271\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews available on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5273\" data-end=\"5276\"\u003e\r\n\u003ch3 data-start=\"5278\" data-end=\"5375\"\u003eWhere can I find additional clinical evidence and detailed information about Dalfampridine?\u003c\/h3\u003e\r\n\u003cp data-start=\"5376\" data-end=\"5468\"\u003eFor further clinical data, dosing guidelines, and safety monitoring information, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"5469\" data-end=\"5848\"\u003e\r\n\u003cli data-start=\"5469\" data-end=\"5557\"\u003e\n\u003cstrong data-start=\"5471\" data-end=\"5523\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5524\" data-end=\"5555\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"5558\" data-end=\"5641\"\u003e\n\u003cstrong data-start=\"5560\" data-end=\"5583\"\u003eClinicalTrials.gov:\u003c\/strong\u003e Search for studies on dalfampridine (e.g., NCT00731639)\u003c\/li\u003e\r\n\u003cli data-start=\"5642\" data-end=\"5750\"\u003e\n\u003cstrong data-start=\"5644\" data-end=\"5655\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed articles on the efficacy and safety of dalfampridine in multiple sclerosis\u003c\/li\u003e\r\n\u003cli data-start=\"5751\" data-end=\"5848\"\u003e\n\u003cstrong data-start=\"5753\" data-end=\"5802\"\u003eWorld Health Organization (WHO) Publications:\u003c\/strong\u003e For guidelines on MS treatment and management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5850\" data-end=\"5904\"\u003e\u003cem data-start=\"5850\" data-end=\"5904\"\u003eReference: U.S. FDA; ClinicalTrials.gov; PubMed; WHO\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5906\" data-end=\"5909\"\u003e\r\n\u003ch3 data-start=\"5911\" data-end=\"5931\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"5932\" data-end=\"6574\"\u003e\u003cstrong data-start=\"5932\" data-end=\"5949\"\u003eDalfampridine\u003c\/strong\u003e (marketed as Ampyra or Fampyra) is an important symptomatic treatment for improving walking in patients with multiple sclerosis. By blocking voltage‑gated potassium channels on demyelinated axons, it enhances nerve conduction and improves mobility. However, due to its potential to lower the seizure threshold and its contraindication in patients with significant renal impairment, dalfampridine must be used with careful patient selection, strict adherence to dosing guidelines, and ongoing monitoring. Always consult your healthcare provider to determine if dalfampridine is appropriate as part of your MS management plan.\u003c\/p\u003e\r\n\u003cp data-start=\"6576\" data-end=\"6800\"\u003e\u003cem data-start=\"6576\" data-end=\"6800\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"10mg","offer_id":51735775281435,"sku":"Dalstep-1-1","price":52.2,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0992\/3303\/8619\/files\/untitled_design_65.png?v=1770408637","url":"https:\/\/ezchemist.com\/products\/dalstep","provider":"EZ Chemist","version":"1.0","type":"link"}